Wells Fargo & Company MN Sells 238,228 Shares of Sanofi (NASDAQ:SNY)

Wells Fargo & Company MN trimmed its position in Sanofi (NASDAQ:SNY - Free Report) by 9.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,255,360 shares of the company's stock after selling 238,228 shares during the period. Wells Fargo & Company MN owned approximately 0.09% of Sanofi worth $112,159,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in SNY. Rise Advisors LLC raised its stake in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company's stock valued at $25,000 after purchasing an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the 4th quarter valued at approximately $27,000. Venturi Wealth Management LLC raised its position in shares of Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company's stock valued at $27,000 after acquiring an additional 332 shares in the last quarter. McIlrath & Eck LLC raised its position in shares of Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company's stock valued at $30,000 after acquiring an additional 361 shares in the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA increased its position in Sanofi by 115.6% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company's stock worth $37,000 after buying an additional 400 shares during the period. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SNY shares. TheStreet cut Sanofi from a "b" rating to a "c" rating in a research note on Friday, February 9th. StockNews.com downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $55.00.

Sanofi Stock Down 2.7 %

Shares of NASDAQ:SNY traded down $1.36 during trading on Thursday, reaching $49.00. 2,781,512 shares of the stock were exchanged, compared to its average volume of 1,993,655. The firm has a market cap of $123.95 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 1.52 and a beta of 0.61. The stock has a fifty day moving average of $48.27 and a two-hundred day moving average of $48.20. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, meeting the consensus estimate of $0.96. The firm had revenue of $11.36 billion for the quarter, compared to analysts' expectations of $11.75 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. Research analysts anticipate that Sanofi will post 4.12 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.38. Sanofi's dividend payout ratio is 74.37%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.